A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
NCT02108652
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
310
Enrollment
INDUSTRY
Sponsor class
Conditions
Bladder Cancer
Interventions
DRUG:
Atezolizumab
Sponsor
Hoffmann-La Roche